Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aimmune Therap (NQ: AIMT )

34.49 USD UNCHANGED
Last Price Updated: 7:11 PM EDT, Oct 12, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Aimmune Therap

< Previous 1 2 3 4 5 6 7 Next >
Detailed Research: Economic Perspectives on Canopy Growth, Aimmune Therapeutics, Nektar Therapeutics, Workday, Workiva, and MAG Silver — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Canopy Growth Corporation... 
From GlobeNewswire News Releases
Aimmune Therapeutics to Participate in Three Investor Conferences in March
Aimmune Therapeutics to Participate in Three Investor Conferences in March 
From Business Wire News Releases
Aimmune Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Recent Operational Highlights
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the fourth quarter and full year... 
From Business Wire News Releases
Aimmune Therapeutics Presents New AR101 Data at AAAAI, Including Demonstrated Reduction in Accidental Exposures to Peanut Requiring Treatment
Aimmune Therapeutics presents new AR101 data at AAAAI, including demonstrated reduction in accidental exposures to peanut requiring treatment. 
From Business Wire News Releases
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host a conference call on Thursday,... 
From Business Wire News Releases
Aimmune Therapeutics to Present AR101, OIT and Peanut Allergy Data at 2019 AAAAI Annual Meeting
Aimmune Therapeutics to present AR101, OIT and peanut allergy data at 2019 AAAAI Annual Meeting. 
From Business Wire News Releases
Aimmune Therapeutics Appoints Andrew Oxtoby as Chief Commercial Officer
Aimmune Therapeutics appoints Andrew Oxtoby as Chief Commercial Officer. 
From Business Wire News Releases
Aimmune Therapeutics and KKR Enter into $170M Loan Agreement to Fund AR101 Commercialization and Pipeline Advancement
Aimmune Therapeutics and KKR enter into $170M Loan agreement to fund AR101 commercialization and pipeline advancement. 
From Business Wire News Releases
Investor Expectations to Drive Momentum within L3 Technologies, The Goldman Sachs Group, Genuine Parts, Bruker, Omeros, and Aimmune Therapeutics — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of L3 Technologies Inc.... 
From GlobeNewswire News Releases
Aimmune Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7th
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CEO Jayson Dallas, M.D., will present a company... 
From Business Wire News Releases
Aimmune Therapeutics Submits BLA to FDA for AR101 for the Treatment of Peanut Allergy in Children and Adolescents Ages 4–17
Aimmune Therapeutics submits BLA to FDA for AR101 for the treatment of peanut allergy in children and adolescents ages 4–17. 
From Business Wire News Releases
Aimmune Therapeutics Announces IND Filing for AR201 for Egg Allergy and Exclusive Supply Agreement with Michael Foods
Aimmune Therapeutics announces IND filing for AR201 for egg allergy and exclusive supply agreement with Michael Foods. 
From Business Wire News Releases
Aimmune Therapeutics Initiates Phase 3 POSEIDON Trial for Treatment of Peanut Allergy in 1–3-Year-Old Children
Aimmune Therapeutics initiates Phase 3 POSEIDON trial for treatment of peanut allergy in 1–3-year-old children. 
From Business Wire News Releases
Aimmune Therapeutics to Host Investor Symposium on the Future of Treating Peanut Allergy with Leading Expert Allergists on Wednesday, December 12th
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Investor Symposium in New York... 
From Business Wire News Releases
Aimmune Therapeutics Announces Closing of $98 Million Investment by Nestlé Health Science
Aimmune Therapeutics announces closing of $98 million investment by Nestlé Health Science. 
From Business Wire News Releases
Market Trends Toward New Normal in Genomic Health, Beacon Roofing Supply, Cronos Group, Aimmune Therapeutics, OGE Energy, and Spartan Motors — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Genomic Health, Inc.... 
From GlobeNewswire News Releases
Landmark PALISADE Trial of AR101 Published in New England Journal of Medicine
Aimmune's landmark PALISADE trial of AR101 for peanut allergy published in the New England Journal of Medicine. 
From Business Wire News Releases
Aimmune Therapeutics Announces Additional Equity Investment by Nestlé Health Science
Aimmune Therapeutics announces additional $98 million equity investment by Nestlé Health Science. 
From Business Wire News Releases
Aimmune Therapeutics Announces Third Quarter 2018 Financial Results and Recent Corporate Highlights
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and nine months ended... 
From Business Wire News Releases
Aimmune Therapeutics Announces Presentations at 2018 ACAAI Annual Scientific Meeting
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data on AR101, oral... 
From Business Wire News Releases
Aimmune Therapeutics Announces Appointment of Dr. Brett Haumann to Board of Directors
Aimmune Therapeutics announces appointment of Dr. Brett Haumann to Board of Directors. 
From Business Wire News Releases
Aimmune Therapeutics to Participate in Upcoming Investor Conferences
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of senior management will participate in... 
From Business Wire News Releases
New Research: Key Drivers of Growth for IDT, Live Nation Entertainment, BioDelivery Sciences International, Spero Therapeutics, Aimmune Therapeutics, and Cars — Factors of Influence, Major Initiatives
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of IDT Corporation... 
From GlobeNewswire News Releases
Aimmune Therapeutics Announces Initiation of Phase 2 Study With Regeneron and Sanofi of AR101 With Adjunctive Dupilumab in Peanut-Allergic Patients
Aimmune Therapeutics announces initiation of phase 2 study with Regeneron and Sanofi of AR101 with adjunctive dupilumab in peanut-allergic patients. 
From Business Wire News Releases
Aimmune Therapeutics to Present at the Cantor Global Healthcare Conference on Wednesday, October 3
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that President and CEO Jayson Dallas, M.D., will... 
From Business Wire News Releases
Aimmune Therapeutics to Present at Three Investor Conferences in September
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of senior management will present at three... 
From Business Wire News Releases
Report: Developing Opportunities within Aimmune Therapeutics, Everbridge, Roku, Bristow Group, Atlas Air Worldwide, and Edgewell Personal Care — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aimmune Therapeutics, Inc.... 
From GlobeNewswire News Releases
Aimmune Therapeutics Announces Second Quarter 2018 Financial Results
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and six months ended... 
From Business Wire News Releases
Aimmune Therapeutics Announces CEO Jayson Dallas Will Present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 15th
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Jayson Dallas, M.D., will give his first public... 
From Business Wire News Releases
Pre-Market Research Reports on Biotech Stocks -- Agenus, Aimmune Therapeutics, Akebia Therapeutics, and Alder Biopharma
From PR Newswire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
X